WealthShield Partners LLC Acquires Shares of 658 Eli Lilly and Company (NYSE:LLY)

WealthShield Partners LLC bought a new stake in Eli Lilly and Company (NYSE:LLYGet Rating) during the second quarter, Holdings Channel reports. The institutional investor bought 658 shares of the company’s stock, valued at approximately $213,000.

Other institutional investors have also made changes to their positions in the company. Cordant Inc. acquired a new stake in shares of Eli Lilly and during the 1st quarter valued at $25,000. Castle Wealth Management LLC acquired a new stake in Eli Lilly and during the second quarter valued at $28,000. Horan Securities Inc. grew its stake in Eli Lilly and by 96.0% in the second quarter. Horan Securities Inc. now owns 98 shares of the company’s stock valued at $32,000 after purchasing an additional 48 shares in the last quarter. Cypress Capital Management LLC WY increased its position in Eli Lilly and by 300.0% in the 2nd quarter. Cypress Capital Management LLC WY now owns 100 shares of the company’s stock worth $32,000 after purchasing an additional 75 shares during the last quarter. Finally, Oliver Lagore Vanvalin Investment Group purchased a new stake in shares of Eli Lilly and during the 1st quarter worth about $33,000. 82.45% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, major shareholder Lilly Endowment Inc sold 400 shares of the company’s stock in a transaction on Wednesday, October 12th. The stock was sold at an average price of $333.50, for a total value of $133,400.00. Following the completion of the transaction, the insider now directly owns 103,624,146 shares in the company, valued at $34,558,652,691. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, major shareholder Lilly Endowment Inc sold 400 shares of the stock in a transaction on Wednesday, October 12th. The shares were sold at an average price of $333.50, for a total value of $133,400.00. Following the completion of the transaction, the insider now owns 103,624,146 shares in the company, valued at approximately $34,558,652,691. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Alonzo Weems sold 656 shares of Eli Lilly and stock in a transaction dated Monday, October 10th. The shares were sold at an average price of $326.23, for a total transaction of $214,006.88. Following the sale, the executive vice president now owns 6,950 shares in the company, valued at $2,267,298.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 571,297 shares of company stock worth $193,929,777. 0.12% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several brokerages recently commented on LLY. Argus boosted their price target on Eli Lilly and from $315.00 to $360.00 in a research note on Friday, September 30th. Barclays increased their price target on shares of Eli Lilly and from $355.00 to $395.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 2nd. BMO Capital Markets lifted their price objective on shares of Eli Lilly and from $369.00 to $396.00 and gave the company an “outperform” rating in a research note on Tuesday, September 6th. Truist Financial increased their target price on shares of Eli Lilly and from $400.00 to $421.00 in a research report on Tuesday, November 15th. Finally, UBS Group raised Eli Lilly and from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $335.00 to $363.00 in a research report on Thursday, September 22nd. Three investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $355.89.

Eli Lilly and Stock Performance

NYSE:LLY opened at $361.67 on Monday. The firm’s 50-day moving average is $335.81 and its 200-day moving average is $320.01. The company has a market cap of $343.65 billion, a price-to-earnings ratio of 54.30, a PEG ratio of 2.28 and a beta of 0.36. The company has a debt-to-equity ratio of 1.39, a quick ratio of 0.88 and a current ratio of 1.13. Eli Lilly and Company has a 52-week low of $231.87 and a 52-week high of $369.80.

Eli Lilly and Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, December 9th. Investors of record on Tuesday, November 15th will be paid a dividend of $0.98 per share. The ex-dividend date of this dividend is Monday, November 14th. This represents a $3.92 annualized dividend and a yield of 1.08%. Eli Lilly and’s dividend payout ratio is 58.86%.

Eli Lilly and Profile

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Read More

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYGet Rating).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.